We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Status: Active

Aug 6th 2020 - Sep 15th 2020

Rescape is a company pioneering the use of Virtual Reality (VR) in healthcare and frontline services. Its DR.VR platform, launched in 2019, helped reduce pain and anxiety amongst patients in hospitals and care homes. The company delivers VR content to patients through the Samsung Gear VR headset, a hard-plastic headset, that can be wiped down and disinfected along with VR sanitary eye masks that reduce chances of infection and irritation to patients. Through the company's technology, patients can experience ocean life, amusements parks and relax in some of the most beautiful settings in the world, all from the safety of the healthcare institution. The AR/VR in Healthcare Market is predicted to reach USD 30-40 billion by 2026, and Rescape aims to be a disruptor in this segment. The company will use the investment to grow its business across different verticals.

read more read less

Rescape Rating Review

Pitch rating powered by CROWDRATING

Rated on 12/08/2020

Pitch Rated

66%

overall

Management

75%

Product

70%

Investment

54%

Log in to view amount pledged

    Log in to view target

    £3,100,166
    pre-money valuation

    8.82%
    equity available

    615
    investors

    £794
    pledge per investor

    11044611
    company number

    Active
    company status

    02/11/2017
    incorporated 7 years

    £1.96
    share price

    Previous Funding rounds
    27 Apr 24 Crowdcube £488,450 / 163% 66.33%

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating

RISK WARNING - The ratings are based on the information provided in the fund raiser’s pitch deck, business plans and financial forecasts which have appeared on a FCA regulated crowdfunding site. Where possible we validate the business plan to public sources such as LinkedIn, Companies House, Credit Agencies and internet searches. We cannot guarantee the information is correct. The ratings report takes no account of the investors/ individual circumstances. Do your own due diligence and get professional advice before investing. Your capital is at risk when investing in private companies.

Login to view the full report

Management 75%

Skills 91%
Rescape has a management team of professionals who come with technical, marketing, and financial skills. The Founder/CEO is skilled in Brand Development, Social Media, Public Relations, Business Development, and Corporate Events. The CTO/Co-Founder is an award-winning creative director who is specialised in Information Architecture, User Experience, Web Development, User Interface Design, and Creative Direction. Their Partnership Manager is passionate about technology innovation, and she is skilled in Business Strategy, Time Management, Relationship Building, Customer Service, and Networking. Their Client Service Manager is skilled in Quality Management, Program Management, Business Planning, Customer Relationship Management, and Logistics. The finances of the company are overseen by their Finance Director who specialises in Contract Negotiation, Risk Management, Financial Analysis, and Project Planning.

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001

Log in to view amount pledged

    Log in to view target

    £3,100,166
    pre-money valuation

    8.82%
    equity available

    615
    investors

    £794
    pledge per investor

    11044611
    company number

    Active
    company status

    02/11/2017
    incorporated 7 years

    £1.96
    share price

    Previous Funding rounds
    27 Apr 24 Crowdcube £488,450 / 163% 66.33%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph